Aarti Pharmalabs Share Price

Aarti Pharmalabs shares have surged 33% in two days after the company reported a 65.4% year-on-year rise in Q1FY27 profit and 38.7% growth in revenue. The rally was further supported by a Rs 149-crore capex plan to add 405 KL of capacity for its CDMO and intermediate businesses.

• Economic Times
• 3 days 7 hours ago

Audio Recording of Conference Call for Investor and Analysts

• BSE India
• 3 days 22 hours ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Aarti Pharmalabs announced Q1FY27 results</strong></span></h3> <p><strong _ngcontent-ng-c1006311636="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> The company reported a net revenue of Rs 53,579.69 lakh in Q1FY27, representing a YoY growth of 38.74% from Rs 38,619.09 lakh in Q1FY26. However, on a QoQ basis, revenue saw a decline of 8.04% from Rs 58,264.40 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Total income for the quarter stood at Rs 53,624.96 lakh, up 38.58% YoY compared to Rs 38,696.22 lakh in Q1FY26. It decreased by 9.22% QoQ from Rs 59,069.56 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit Before Tax (PBT):</strong> Consolidated PBT grew to Rs 10,106.02 lakh in Q1FY27, marking a YoY increase of 66.17% from Rs 6,081.73 lakh in Q1FY26 and a QoQ growth of 23.73% from Rs 8,167.86 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Net Profit:</strong> The company posted a net profit of Rs 7,614.27 lakh in Q1FY27, reflecting a significant growth of 65.42% YoY from Rs 4,603.09 lakh in Q1FY26 and a 24.57% increase QoQ from Rs 6,112.41 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Earnings Per Share (EPS):</strong> Basic EPS improved to Rs 8.40 in Q1FY27, compared to Rs 5.08 in Q1FY26 and Rs 6.74 in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Full Year FY26 Performance:</strong> For the full year ended March 31, 2026, the company recorded total income of Rs 1,82,918.89 lakh and a net profit of Rs 17,470.73 lakh.</li> </ul> <p><strong _ngcontent-ng-c1006311636="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> Standalone net revenue was Rs 53,458.78 lakh in Q1FY27, reflecting a YoY growth of 42.44% from Rs 37,531.06 lakh in Q1FY26 and a QoQ decrease of 7.78% from Rs 57,970.05 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Total standalone income stood at Rs 53,751.91 lakh, an increase of 42.93% YoY and a decrease of 8.93% QoQ compared to Rs 37,608.19 lakh in Q1FY26 and Rs 59,023.06 lakh in Q4FY26, respectively.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Net Profit:</strong> Standalone net profit for Q1FY27 reached Rs 7,130.66 lakh, up 49.33% YoY from Rs 4,775.05 lakh in Q1FY26 and up 14.95% QoQ from Rs 6,203.07 lakh in Q4FY26.</li> </ul> <p><strong _ngcontent-ng-c1006311636="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Segment Performance:</strong> The company operates exclusively within a single reportable segment, "Pharmaceuticals".</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Capacity Expansion:</strong> The Board of Directors approved a capacity addition for the "Development of Intermediate Block" with an estimated capital expenditure (capex) of Rs 149 crore. This project involves a proposed capacity addition of 405 Kl and is expected to be completed within one year.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Strategic Rationale:</strong> The expansion is intended to serve the company's intermediate and CDMO (Contract Development and Manufacturing Organization) customers.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Management Restructuring:</strong> The Board approved change in roles for senior management, effective from October 1, 2026. Shri. Rashesh C. Gogri will transition from Non-Executive Director to Managing Director, and Smt. Hetal Gogri Gala will transition from Managing Director to Executive Director, subject to shareholder approval.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Equity Allotment:</strong> The company allotted 1,35,480 equity shares of Re 1/- each following the exercise of options under its 2023 ESOP plan at an exercise price of Rs 14.10 per share.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5773480/" target="_blank">Result PDF</a></p>

• Trendlyne
• 4 days 4 hours ago